Xeris Biopharma Holdings XERS
NASDAQ XERS
$16.57 +0.05 (+0.30%)
As of: Nov 12, 2026 · 10:03 AM EST

Xeris Biopharma Holdings (XERS) Return on Sales [ROS] (2020 - 2026)

Updated

Xeris Biopharma Holdings (XERS) recorded Return on Sales [ROS] of 5.62% in Q2 2026, down 0.65 percentage points from 6.27% a year earlier and down 3.91 percentage points from the prior quarter.

Analysis

Xeris Biopharma Holdings (XERS) Return on Sales [ROS] (2020 - 2026) Analysis & Trends

On a TTM basis, Xeris Biopharma Holdings' Return on Sales [ROS] came in at 10.91% as of Jun 30, 2026, up 14.90 percentage points year-over-year; for FY2025, it came in at 8.53%, up 25.10 percentage points from FY2024.

  • Annual Return on Sales [ROS] has increased for five straight years, with a five-year change of +417.37 percentage points (FY2020 to FY2025).
  • Across earlier years, Return on Sales [ROS] came in at -16.57% in FY2024 (+10.28 pp), -26.85% in FY2023 (+47.47 pp), -74.32% in FY2022 (+157.89 pp) and -232.22% in FY2021 (+176.62 pp).
  • The Q2 2026 figure is the lowest quarterly Return on Sales [ROS] since Q1 2025.
  • On a year-over-year basis, Return on Sales [ROS] rose in six of the last eight quarters, with an average year-over-year change of +16.02 percentage points.
  • Peak year-over-year performance for Return on Sales [ROS] in the last five years was a gain of 214.80 percentage points in Q2 2022, against a drop of 74.08 percentage points in Q3 2021 at the low end.
  • Per Business Quant, the preceding three quarters came in at 9.52% (Q1 2026), 19.55% (Q4 2025) and 9.05% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Xeris Biopharma Holdings 2.89 Bn 2.41 Bn 94.80 Mn 15.78%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 15.78%
Jun 30, 2026 5.62%
Mar 31, 2026 9.52%
Dec 31, 2025 19.55%
Sep 30, 2025 9.05%
Jun 30, 2025 6.27%
Mar 31, 2025 -5.14%
Dec 31, 2024 2.79%
Sep 30, 2024 -23.76%
Jun 30, 2024 -17.03%
Mar 31, 2024 -35.05%
Dec 31, 2023 -22.17%
Sep 30, 2023 -10.17%
Jun 30, 2023 -42.04%
Mar 31, 2023 -40.00%
Dec 31, 2022 -45.77%
Sep 30, 2022 -63.18%
Jun 30, 2022 -74.75%
Mar 31, 2022 -131.72%
Dec 31, 2021 -225.26%
API Access

Xeris Biopharma Holdings Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=XERS&period=max&api_key=YOUR_API_KEY